Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20310514 | 1.00 | PNP (0.54) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL13351290 | 1.00 | PNP (0.54) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL13318964 | 1.00 | PNP (0.54) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL657360 | 1.00 | PNP (0.54) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL14543297 | 1.00 | PNP (0.54) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL10109648 | 1.00 | PNP (0.54) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL1401218 | 0.96 | PNP (0.51) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL7047708 | 0.91 | ADORA3 (0.54) | PNPALDH1A1MAPTBLMPMP22 | |
| SCHEMBL655857 | 0.89 | PNP (0.65) | PNPMAPTCYP3A4ADRB1DNMT1 | |
| SCHEMBL655858 | 0.89 | PNP (0.65) | PNPMAPTCYP3A4ADRB1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4539205-A | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-09-03 | — | — | US | claimed |
| WO-2026106815-A1 | Z-INDUCING CHIMERA COMPOSITION | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| EP-4555086-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | ProQR Therapeutics II B.V. (NL) | 2025-05-21 | — | — | EP | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| WO-2024013361-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | PROQR THERAPEUTICS II B.V. (NL) | 2024-01-18 | — | — | WO | disclosed |
| CN-117343990-A | Method and kit for determining target polynucleotide and probe set | 牛津纳米孔科技公开有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-0504279-A4 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | — | 1993-02-17 | — | — | EP | disclosed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | disclosed |
| US-5147636-A | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives and interferons | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-09-15 | — | — | US | disclosed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| US-4948730-A | INDUCING INTERFERON PRODUCTION | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-08-14 | — | — | US | disclosed |
| US-4849411-A | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-07-18 | — | — | US | disclosed |
| US-4643992-A | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1987-02-17 | — | — | US | disclosed |
| US-4539205-A | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1985-09-03 | — | — | US | disclosed |
| EP-0112632-A2 | Use of 8-substituted guanine derivatives in the manufacture of a medicament. | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1984-07-04 | — | — | EP | disclosed |
| WO-1984001898-A1 | MODULATION OF ANIMAL CELLULAR RESPONSES WITH COMPOSITIONS CONTAINNG 8-SUBSTITUTED GUANINE DERIVATIVES | SCRIPPS CLINIC RES (US) | 1984-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | PNP 8/4885ALDH1A1 4810/4885MAPT 3486/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | PNP 487/4885ALDH1A1 4286/4885MAPT 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.